Altoida, a pioneer in digital biomarkers for neurological diseases using augmented reality and machine learning, has reported the results of a study involving 188 participants. Their digital cognitive assessment, based on AR and ML, effectively identified individuals with mild cognitive impairment. This assessment offers an objective measure of cognitive and functional abilities in about 10 minutes, in contrast to traditional pen-and-paper neuropsychological tests that take much longer.
The study demonstrated that Altoida's digital cognitive assessment correlates with standard neuropsychological tests like the Mini-Mental State Examination (MMSE), Free and Cued Selective Reminding Test (FCSRT), and the Trail Making Test (TMT). The assessment provides a Digital Neuro-Signature (DNS-MCI) score that correlates with classical neuropsychological tests used in clinical research and practice. Altoida's digital cognitive assessment is seen as a potential tool for more frequent and unbiased measurements of cognitive function, eliminating the need for a trained rater.
The study was conducted with 188 participants in a dual-centre, cross-sectional cohort study and classified participants as cognitively normal or having mild cognitive impairment. Altoida has also been involved in the Digital Health Measurement Collaborative Community, which recently released a resource to guide the work of clinicians and researchers using digital tools for Alzheimer's Disease and Related Dementias (ADRD) patients, helping improve measurement parameters for research and care.
Click here to read the original news story.